Call Us: 1.800.873.5297


Actos® MDL Trial Update (MDL 2299): Judge Rules that Jury Can Hear Claims Over Takeda’s Destroyed Files

Bloomberg reports that The Honorable Judge Rebecca F. Doherty, who presides over the Actos® Multidistrict Litigation (MDL 2299), has decided that Takeda must allow the jury for the first federal trial to hear claims that it intentionally destroyed files related to its Actos® diabetes drug.

Officials at the Osaka, Japan-based Takeda admitted they cannot find the files compiled by over 45 current and former Takeda employees involved within the marketing and sales department – two of which are directors. After finding that some files were deleted from company computers after executives warned employees to retain Actos®-related materials, Judge Doherty said that “the breadth of Takeda leadership whose files have been lost, deleted or destroyed is, in and of itself, disturbing.” As punishment, Judge Doherty has ruled that she will allow plaintiff’s attorneys to tell jurors about the document destruction during the trial.

The first trial in the Multidistrict Litigation In re: Actos® (Pioglitazone) Products Liability Litigation, MDL 2299 is underway in the United States District Court for the Western District of Louisiana before The Honorable Judge Rebecca F. Doherty and is expected to last six weeks. According to the most recent report issued by the Judicial Panel on Multidistrict Litigation, there are nearly 2,700 cases currently on file against Takeda Pharmaceuticals, the manufacturer of the diabetes drug Actos®, in MDL 2299.

In addition to the Multidistrict Litigation (MDL 2299) pending in federal court, there is a consolidated state court litigation pending in Cook County Circuit Court in Chicago, Illinois. There are approximately 3,000 Actos® bladder cancer cases currently on file against Takeda Pharmaceuticals in Cook County before The Honorable Judge Deborah Mary Dooling (In re Actos® Litigation, Case No. 2011 L 10011). The first trial in the Cook County Actos® litigation is scheduled to begin in March 2014.

Actos® is a medication prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. The Food and Drug Administration (“FDA”) approved Actos® in 1999. The drug subsequently became the world’s best-selling diabetes treatment with Actos® sales peaking between March 2010 and March 2011 at $4.5 billion, or 27 percent of Takeda revenue, according to data compiled by Bloomberg News. In June 2011, the FDA issued a Drug Safety Alert warning that the use of Actos® for more than one year may be associated with an increased risk of bladder cancer. According to Bloomberg, Actos® has generated more than $16 billion in sales since its 1999 release.

Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries. If you or a loved one developed bladder cancer after taking Actos® for more than one year, please contact Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.


The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.